drugset
Drugs / F520
last change Aug 2026 re-read 2 minutes ago

F520

also known as Rulonilimab

Monoclonal antibody

Developed for
cervical cancer · cancer · central nervous system non-hodgkin lymphoma · hepatocellular carcinoma · Hodgkin's lymphoma, lymphocytic depletion · non-small cell lung carcinoma · peripheral T-cell lymphoma, not otherwise specified · relapsed/refractory diffuse large B-cell lymphoma
+1 more · urothelial carcinoma
Investigated by
Shandong New Time Pharmaceutical Co., LTD

Trials 10 · a red edge is where a trial was stopped

today NCT06755515 · Ph 2/3 NCT05741021 · Ph 2 NCT05408221 · Ph 2/3 NCT05740215 · Ph 1/2 NCT05178836 · Ph 2 NCT06226350 · Ph 2 NCT04636515 · Ph 2 NCT04457830 · Ph 2 NCT04457869 · Ph 2 NCT03657381 · Ph 1
2019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03657381 Mar 2019 → Feb 2021 Hodgkin's lymphoma, lymphocytic depletion Shandong New Time Pharmaceutical Co., LTD Unknown No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05740215 May 2022 → May 2024 cancer Shandong New Time Pharmaceutical Co., LTD Unknown No outcome recorded
Phase 26 trials
Phase 2 NCT05741021 Mar 2023 → Oct 2024 non-small cell lung carcinoma Shandong New Time Pharmaceutical Co., LTD Unknown No outcome recorded
Phase 2 NCT05178836 Jan 2022 → Dec 2023 relapsed/refractory diffuse large B-cell lymphoma Shandong New Time Pharmaceutical Co., LTD Unknown No outcome recorded
Phase 2 NCT06226350 Mar 2021 → Dec 2023 cervical cancer Shandong New Time Pharmaceutical Co., LTD Completed No outcome recorded
Phase 2 NCT04636515 Jan 2021 → Mar 2022 urothelial carcinoma Shandong New Time Pharmaceutical Co., LTD Unknown No outcome recorded
Phase 2 NCT04457830 Nov 2020 → Jul 2022 peripheral T-cell lymphoma, not otherwise specified Shandong New Time Pharmaceutical Co., LTD Unknown No outcome recorded
Phase 2 NCT04457869 Nov 2020 → Jul 2022 central nervous system non-hodgkin lymphoma Shandong New Time Pharmaceutical Co., LTD Unknown No outcome recorded
Phase 2/32 trials
Phase 2/3 NCT06755515 Sep 2024 → Sep 2028 expected cervical cancer Shandong New Time Pharmaceutical Co., LTD Enrolling by invitation No outcome recorded
Phase 2/3 NCT05408221 Nov 2022 → Aug 2025 overdue hepatocellular carcinoma Shandong New Time Pharmaceutical Co., LTD Recruiting No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

FieldValueCited text
Known as F520 “F520,IV, 3mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.” NCT06226350 ↗
7

“Recombinant Programmed death-1(PD-1) humanized monoclonal antibody injection (company code: F520)” NCT03657381 ↗

NCT04457830 ↗

NCT05178836 ↗

NCT04636515 ↗

NCT05740215 ↗

NCT05741021 ↗

NCT04457869 ↗
Known as Rulonilimab ClinicalTrials.gov intervention name — accepted as the source's own label NCT05408221 ↗
1

NCT06755515 ↗
Action Inhibit “prevents binding of PD-1 with programmed death ligands 1 (PD-L1) and 2 (PD-L2)” NCT05178836 ↗
Modality Monoclonal antibody “humanized monoclonal antibody” NCT03657381 ↗
Route Intravenous “F520 (200mg) administered intravenously (IV) on Day 2 of each 14-day cycle for cycle 1.” NCT05178836 ↗